Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF kinase inhibitors: how do they cause hypertension?

(2009) Pankaj Bhargava   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Hypertension as a surrogate marker for the activity of anti-VEGF agents

(2009) O. Mir et al.   ANNALS OF ONCOLOGY

Rapid Development of Hypertension by Sorafenib: Toxicity or Target?

(2009) B. D. Humphreys et al.   CLINICAL CANCER RESEARCH

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

(2009) Carie S. Facemire et al.   HYPERTENSION

Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors

(2009) Marlies H.G. Langenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1

(2009) Kwan-Hyuck Baek et al.   NATURE

Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy

(2008) T.-Y. Lee et al.   CLINICAL CANCER RESEARCH

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

(2008) Shenhong Wu et al.   LANCET ONCOLOGY